Deep search
Profile Picture
  • All
  • Search
  • Images
  • Videos
  • Maps
  • News
  • Copilot
  • More
    • Shopping
    • Flights
    • Travel
    • Hotels
  • Notebook
  • Top stories
  • Sports
  • U.S.
  • Local
  • World
  • Science
  • Technology
  • Entertainment
  • Business
  • More
    Politics
  • Any time
    • Past hour
    • Past 24 hours
    • Past 7 days
    • Past 30 days
  • Best match
    • Most recent

News

KalVista, Hereditary Angioedema and FDA

Reuters on MSN · 1d
US FDA approves KalVista's oral swelling disorder drug, shares rise
KalVista Pharmaceuticals said on Monday the U.S. Food and Drug Administration has approved its drug, the first on-demand oral treatment for a type of hereditary swelling disorder, sending its shares up more than 18%.
Business Wire · 2d
KalVista Pharmaceuticals Announces FDA Approval of EKTERLY® (sebetralstat), First and Only Oral On-demand Treatment for Hereditary Angioedema
KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced that the U.S. Food and Drug Administration (FDA) has approved EKTERLY® (sebetralstat), a novel
PharmExec · 22h
FDA Approves KalVista Pharmaceuticals’ Ekterly for Hereditary Angioedema
Ekterly becomes the first FDA-approved oral on-demand treatment for hereditary angioedema in patients aged 12 years and older.
BioSpace
1h
Second Half Milestones, KalVista’s Surprise Approval, Another RFK Jr. Lawsuit, More
H2 2025 catalysts to watch, biopharma implications of President Trump’s tax law, KalVista’s new hereditary angioedema drug that Marty Makary reportedly tried to reject, another lawsuit aimed at Health ...
1d
Orsini Selected as Specialty Pharmacy Partner for KalVista's EKTERLY® (sebetralstat)
Orsini, a leader in rare disease pharmacy solutions, has been chosen by KalVista Pharmaceuticals as a specialty pharmacy ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results

Trending now

Abbott: 160+ still missing
How to help TX flood victims
Cause of death revealed
'Click-to-cancel' blocked
Files for 'blue chip' ETF
Floats 200% pharma tariffs
Trash piles up in Philly
Family members swept away
Chinese man charged
Named Apple's new COO
Italy outraged at killing
Sentencing set for October 3
Clears way for mass firings
Discharged from hospital
Ship attacked in Red Sea
Greece shuts Acropolis
Says churches can endorse
Milan airport tragedy
Invests in EssilorLuxottica
Jones enters governor's race
Judge: Case should proceed
Wins malaria drug approval
Linqto files for bankruptcy
ICE facility attack arrests
UK Post Office scandal
WI conversion therapy ruling
Appoints new CEO
Osborn launches Senate bid
Rubio impersonator used AI
To be displayed in the UK
Reveals new book club pick
Eyes NYC, DC takeover
Feedback
© 2025 Microsoft
  • Privacy and Cookies
  • Legal
  • Advertise
  • About our ads
  • Help
  • Feedback
  • Your Privacy Choices
  • Consumer Health Privacy